Ismael J. Hidalgo

Ismael J. Hidalgo

Auto-generated profile, based on publicly available information

Ismael J. Hidalgo

Absorption Systems, Exton PA1 9341, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JLJibin Li
Jibin Li
DVDonna A. Volpe
Donna A. Volpe
YWYing Wang
Ying Wang
WZWei Zhang
Wei Zhang
CBChris Bode
Chris Bode
IHIsmael J. Hidalgo
Ismael J. Hidalgo
The objective of the present study was to determine the efflux transporters responsible for acid and lactone statin drug efflux using transporter knockdown Caco-2 cells. The bidirectional transport was determined in Caco-2 cell monolayers in which the expression of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or multidrug resistance associated protein 2 (MRP2) was knocked down by transduction with lentivirus containing human transporter-targeted small hairpin RNAs (shRNAs). Cells transduced with lentivirus containing nontargeted shRNA served as the vector control. Atorvastatin, lovastatin, and rosuvastatin displayed extremely low apical-to-basolateral (A-to-B) transport, which made the Papp,A-B values too unreliable to calculate the efflux ratio. Thus, transport comparisons were performed using the B-to-A permeability (Papp,B-A) values. Presented in the order of vector control, P-gp, BCRP, and MRP2 knockdown Caco-2 cells, the Papp,B-A values (×10−6, cm/s) were 28.1 ± 1.3, 8.6 ± 2.9, 20.3 ± 1.8, and 21.5 ± 1.6 for atorvastatin; 96.1 ± 7.1, 25.3 ± 3.5, 57.3 ± 9.8, and 48.2 ± 2.3 for fluvastatin; and 14.1 ± 1.9, 4.6 ± 1.7, 5.8 ± 0.7, and 6.6 ± 1.8 for rosuvastatin, respectively. Lovastatin and simvastatin showed no efflux in the vector control or knockdown cell monolayers in either lactone or acid forms. Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. On the other hand, neither the lactone nor the resulting acid of lovastatin and simvastatin was transported by P-gp, BCRP, or MRP2. The current study demonstrated that the transporter knockdown Caco-2 cells are useful tools for studying drug-transporter interactions and should help eliminate some of the ambiguity associated with the identification of drug-transporter interactions based on chemical inhibitors alone.

1 July 2009 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TSTomotaka Shingaki
Tomotaka Shingaki
IHIsmael J. Hidalgo
Ismael J. Hidalgo
Tomoyuki FurubayashiTomoyuki Furubayashi
Tomoyuki Furubayashi
HKHidemasa Katsumi
Hidemasa Katsumi
TSToshiyasu Sakane
Toshiyasu Sakane
SYShinji Yamashita
Shinji Yamashita

16 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ALAnnie Albin Lumen
Annie Albin Lumen
LLLibin Li
Libin Li
JLJiben Li
Jiben Li
ZAZeba Ahmed
Zeba Ahmed
ZMZhou Meng
Zhou Meng
JBJoe Bentz
Joe Bentz
We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-NKI (The Netherlands Cancer Institute) confluent cell monolayers. That is, GF120918 inhibitable uptake transport was kinetically required. Therefore, IC50 measurements using digoxin as a probe substrate in this cell line could be due to inhibition of P-gp, of digoxin uptake transport, or both. This kinetic analysis is now extended to include three additional cell lines: MDCK-MDR1-NIH (National Institute of Health), Caco-2 and CPT-B2 (Caco-2 cells with BCRP knockdown). These cells similarly exhibit GF120918 inhibitable uptake transport of digoxin. We demonstrate that inhibition of digoxin transport across these cell lines by GF120918, cyclosporine, ketoconazole and verapamil is greater than can be explained by inhibition of P-gp alone. We examined three hypotheses for this non-P-gp inhibition. The inhibitors can: (1) bind to a basolateral digoxin uptake transporter, thereby inhibiting digoxin's cellular uptake; (2) partition into the basolateral membrane and directly reduce membrane permeability; (3) aggregate with digoxin in the donor chamber, thereby reducing the free concentration of digoxin, with concomitant reduction in digoxin uptake. Data and simulations show that hypothesis 1 was found to be uniformly acceptable. Hypothesis 2 was found to be uniformly unlikely. Hypothesis 3 was unlikely for GF120918 and cyclosporine, but further studies are needed to completely adjudicate whether hetero-dimerization contributes to the non-P-gp inhibition for ketoconazole and verapamil. We also find that P-gp substrates with relatively low passive permeability such as digoxin, loperamide and vinblastine kinetically require basolateral uptake transport over that allowed by +GF120918 passive permeability, while highly permeable P-gp substrates such as amprenavir, quinidine, ketoconazole and verapamil do not, regardless of whether they actually use the basolateral transporter.

1 January 2011 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TSTomotaka Shingaki
Tomotaka Shingaki
IHIsmael J. Hidalgo
Ismael J. Hidalgo
Tomoyuki FurubayashiTomoyuki Furubayashi
Tomoyuki Furubayashi
TSToshiyasu Sakane
Toshiyasu Sakane
HKHidemasa Katsumi
Hidemasa Katsumi
SYShinji Yamashita
Shinji Yamashita
The objective of this study was to evaluate in rats the potential utility of the nasal route to enhance central nervous system (CNS) delivery of drugs recognized by P-glycoprotein (P-gp). Well-known P-gp substrates verapamil and talinolol were perfused nasally or infused intravenously, and when plasma concentrations following intravenous infusion and nasal perfusion showed similar profiles. The concentration of verapamil in the brain after nasal perfusion was twice that after intravenous infusion. Although talinolol in the brain and the cerebrospinal fluid after i.v. infusion were below the detection limit, it was detected after nasal perfusion. When rats were treated with cyclosporin A, brain concentrations of verapamil after both administration modes were increased significantly, while those of talinolol were not significantly changed. Since the permeability of talinolol is low, talinolol in the brain which was transported directly from the nasal cavity has little chance of transport by P-gp localized in the apical membrane of cerebral microvessel endothelial cells. The potential for drug delivery utilizing the nose-CNS route was confirmed for P-gp substrates. The advantage of nasal delivery over i.v. delivery of talinolol to the brain was more significant than that of verapamil, suggesting that nasal administration is more useful strategy for the brain delivery of low-permeability P-gp substrates than the use of P-gp inhibitors.

1 September 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
JLJibin Li
Jibin Li
YWYing Wang
Ying Wang
IHIsmael J. Hidalgo
Ismael J. Hidalgo

1 May 2021 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
VGVibhor Gupta
Vibhor Gupta
SLSílvia P. Lourenço
Sílvia P. Lourenço
IHIsmael J. Hidalgo
Ismael J. Hidalgo